share_log

Invitae Released A New Study In JAMA Network Open Clinical Practice Guidelines Recommend Genetic Testing Of All Patients With Breast Cancer

Invitae Released A New Study In JAMA Network Open Clinical Practice Guidelines Recommend Genetic Testing Of All Patients With Breast Cancer

Invitae在JAMA网络上发布的一项新研究开放临床实践指南建议对所有乳腺癌患者进行基因检测
Benzinga Real-time News ·  2022/09/22 11:02
Invitae study reports universal genetic testing improves outcomes for patients with breast cancer –
Invitae研究报告称,通用基因检测改善了乳腺癌患者的预后 –
SAN FRANCISCO, Sept. 22, 2022 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, released a new study in JAMA Network Open, underscoring the clinical utility of the American Society of Breast Surgeons (ASBrS) guidelines recommending universal genetic testing for patients with breast cancer, and showing universal testing improves patient outcomes. Building on a previous study reported in the Journal of Clinical Oncology, the current study is the first clinical outcomes study of a cohort of unselected patients with breast cancer who underwent universal germline genetic testing. Our data...
旧金山,9月2022年2月22日/美通社/--领先的医学遗传学公司Invitae(纽约证券交易所代码:NVTA)在JAMA网络开放强调了美国乳房外科学会(ASBRS)指南建议...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发